Clinical Trial Update: H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial results update for a combined H3.3K27M peptide vaccine and nivolumab in children with newly diagnosed Diffuse Intrinsic Pontine Glioma and other …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Intrinsic Pontine Glioma
• Diffuse Midline Glioma H3 K27m-mutant
• Glioma

Drugs mentioned

• H3.3K27M peptide vaccine (H3.3K27M peptide vaccine)
• nivolumab (nivolumab)

Snippet

Sponsor: Sabine Mueller, MD, PhD | Conditions: Diffuse Intrinsic Pontine Glioma, Glioma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-01-22